肽治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00003793
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 198
Buy Now

[研究报告]肽治疗市场规模预计将从2020年的269.9821亿美元增长到2027年的500.0315亿美元;预计从 2020 年到 2027 年,肽治疗市场将以 9.2% 的复合年增长率增长。

分析师观点

肽治疗市场很可能由于人们越来越重视开发新型肽疗法以及肽在再生医学方面的潜力,该领域的增长。此外,由于不断扩大的产品线和肽治疗药物的强劲研发,市场可能会产生积极影响。此外,癌症、糖尿病和呼吸系统疾病发病率的显着增加导致对肽疗法的需求不断增长。此外,市场上运营的公司积极参与研发,并专注于扩大发展中地区的客户群。例如,2023年5月,SynCrest Inc.通过大冢化学株式会社和横河电机株式会社的合资企业推出了基于肽的疗法的CRDMO服务。该服务将提供给日本、欧洲、北美和南美的制药公司和研究机构。这些战略决策也将促进 2020 年和 2027 年的市场增长。

市场概览

肽是天然存在的生物分子,在重要的生物活性。人们在药物研发(R&D)方面做出了广泛的努力,以创新治疗慢性病的新肽。近年来,已鉴定出超过 7000 种天然存在的肽,它们在人类生理学中发挥着至关重要的作用,包括神经递质、激素、离子通道配体和生长因子等作用。肽治疗市场的增长归因于几个关键因素,例如对肽治疗的投资不断增加以及全球慢性疾病和传染病的患病率不断增加,预计将推动市场增长。然而,肽的操作限制预计将阻碍市场增长。全球肽治疗市场按类型、给药途径、合成技术和应用细分。根据地理位置,全球肽治疗市场分为北美、欧洲、亚太地区、中东和南美地区。中美洲。

战略洞察

市场驱动力

肽治疗投资不断增长

持续肽疗法的研发活动已发现其在解决一系列慢性疾病方面的益处,例如肾脏疾病、遗传疾病、肿瘤学和神经退行性疾病。肽疗法的效果的有效性正在为新药开发带来投资。例如,2020年12月,Peptilogics通过多轮系列融资获得了约3540万美元的资金。这笔资金将加速其肽治疗候选药物 PLG0206 的开发。此外,2020年10月,Lassogen通过多轮系列融资筹集了450万美元,用于lasso肽的开发。据该公司称,该肽有望为癌症、自身免疫、疼痛和炎症提供卓越的治疗效果。此外,2020 年 12 月,ONL Therapeutics 为其治疗视网膜疾病的 ONL1204 候选肽完成了几轮系列融资(4690 万美元)。

这些公司还专注于扩大投资以扩大其在肽市场的业务。例如,2019年3月,美国Creative Peptides公司推出了新的药物肽服务,旨在扩展肽在药物发现中的应用。此外,2019年10月,UCB宣布计划收购RA Pharmaceuticals,以扩大其多肽药物组合。目前,RA Pharmaceutical 的产品正在研发中。此类投资预计将在预测期内加速肽治疗市场的增长。

细分分析

全球肽治疗市场已细分根据类型、给药途径、合成技术和应用。根据类型,市场分为通用型和创新型。 2020年,创新细分市场占据最大的市场份额。为患者提供治疗特定疾病的新型肽药物被称为创新肽药物。这些创新药物有助于为患者提供比市场上现有药物更好的治疗效果。该制药公司投入大量资金来开发此类新颖的药品。该公司的药品已获得专利批准,其他任何公司都不能生产该药品,该药品属于该公司专有。肽类药物越来越多的批准可能有利于市场增长。 2015年至2019年间,美国食品药品监督管理局(FDA)共批准了208个新药(150个新化学实体和58个生物制剂),其中15个是肽或含肽分子,占总数的7%药物数量。例如,诺和诺德的 Ozempic(索马鲁肽)于 2020 年 1 月获得美国食品和药物管理局 (FDA) 批准,用于降低成人 2 型糖尿病患者发生中风、心脏病或死亡等心血管事件的风险。因此,此类实例正在利用该细分市场的增长。然而,预计仿制药细分市场将在 2020-2027 年实现最高的复合年增长率。

根据给药途径,市场分为肠外、口服、粘膜、肺部等。注射剂细分市场在 2020 年占据最大的市场份额,预计口服细分市场在预测期内的复合年增长率最高。

基于综合分析技术方面,市场分为固相肽合成(SPPS)、液相肽合成(LPPS)、混合技术。固相肽合成领域在 2020 年占据最大的市场份额,混合技术领域预计将在 2020-2027 年实现最高的复合年增长率。

基于根据应用,肽治疗市场分为癌症、心血管疾病、代谢疾病、呼吸系统疾病、疼痛和皮肤病。癌症细分市场在 2020 年占据最大的市场份额。然而,代谢紊乱细分市场预计在此期间的市场复合年增长率最高。

区域分析

北美在全球肽治疗市场中占有最大的市场份额,2020年价值为108.6948亿美元,预计从2020年到2027年将以9.4%的复合年增长率增长。北美肽治疗市场分为美国、加拿大和墨西哥。 2019年,美国在北美肽疗法市场中占据最大份额。人们对肽类药物的认识不断增强,对药物发现的投资不断增加,以及对慢性病管理替代疗法的需求不断增长,预计将推动美国肽疗法的增长预测期内的市场。

在加拿大,由于医疗保健系统的发展和现代细胞相关技术的迅速采用,预计该市场将增长。另一方面,由于人们对肽疗法的益处的认识不断提高以及政府投资的增加,墨西哥可能会经历市场增长机会。然而,由于对优质治疗解决方案的需求不断增加、有利的监管环境、对研发活动的日益关注以及对肽疗法所带来的益处的认识不断提高等因素,亚太地区估计是增长最快的地区。此外,发展医疗基础设施和增加投资以促进研究活动预计将在预测期内推动亚太地区肽治疗市场的发展。

关键参与者分析

肽治疗市场主要由礼来公司、安进公司、梯瓦制药工业有限公司、多肽集团、EVER Pharma GmbH、百时美施贵宝公司、诺和诺德公司、赛诺菲等公司组成、阿斯利康公司和葛兰素史克公司等。市场上的两家领先企业是礼来公司和安进公司。这些公司参与了各种有机和无机开发,为重大增长机会铺平了道路。

< h3>近期发展

肽治疗市场的公司高度采用无机和有机策略。下面列出了最近的一些关键市场动态:

  • 2020 年 11 月,诺和诺德利用 Emisphere 的 Eligen SNAC 药物输送技术开发了 Rybelsus。诺和诺德 (Novo Nordisk) 收购了 Emisphere,这使得前者能够获得对 Eligen 平台的控制权,并消除未来对后者公司的特许权使用费义务。
  • 2020 年 2 月,BioMotiv 和百时美施贵宝公司(纽约证券交易所股票代码:BMY) )今天宣布推出 Anteros Pharmaceuticals,这是一家生物技术公司,专注于开发一类治疗纤维化和其他炎症性疾病的新型药物。根据合作条款,百时美施贵宝将针对未公开的机制贡献一系列小分子的知识产权、数据和试剂,而 BioMotiv 将通过组建 Anteros Pharmaceuticals 与耶鲁大学密切合作,全权负责研发。一旦 Anteros 提名临床前候选药物,百时美施贵宝可以选择根据预先商定的条款从 BioMotiv 收购该公司。
  • 2020 年 12 月,礼来公司公布了其替泽帕肽药物的结果2型糖尿病管理候选人。结果显示,该产品具有降低2型糖尿病患者A1C和体重的功效。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the major players in the peptide therapeutics market?

The peptide therapeutics market majorly consists of the players such as Eli Lilly and Company, Amgen Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Polypeptide Group, EVER Pharma GmbH, Bristol-Myers Squibb Company, Novo Nordisk A/S, Sanofi, AstraZeneca PLC, and Glaxosmithkline PLC amongst others.

What are peptide therapeutics?

Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. There are extensive efforts have been taken in pharmaceutical research and development (R&D) to innovate new peptides for the treatment of chronic conditions. Over 7000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors, amongst others.

What are the driving factors for the peptide therapeutics market across the globe?

The growth of the market is attributed to some key driving factors such as growing investments on peptide therapeutics and increasing prevalence of metabolic and infectious diseases.

The List of Companies - Peptide Therapeutics Market

  1. Eli Lilly and Company
  2. Amgen Inc.
  3. TEVA PHARMACEUTICAL INDUSTRIES LTD
  4. Polypeptide Group
  5. EVER Pharma GmbH
  6. Bristol-Myers Squibb Company
  7. Novo Nordisk A/S
  8. Sanofi
  9. AstraZeneca PLC
  10. Glaxosmithkline PLC  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports